Skip to content
PeptidesEncyclopedia
For research use only

Not for human consumption. Consult a licensed professional.

Research chemical — not approvedaka Growth Hormone Releasing Peptide-6

GHRP-6 — Complete Research Guide (2026)

Last updated 2026-06-25

TL;DR

A first-generation growth-hormone-releasing hexapeptide and ghrelin-receptor agonist studied for GH stimulation and appetite effects.

What is GHRP-6?

GHRP-6 (growth-hormone-releasing peptide-6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHSR1a) and also binds the scavenger receptor CD36.

Its human data are limited to older GH-stimulation and pharmacology studies, while most newer research is preclinical (animal/in-vitro), particularly in cardioprotection and cytoprotection; it is not approved for any therapeutic use.

It is presented here for research and educational purposes only, not as a therapy or performance product.

How does GHRP-6 work?

GHRP-6 stimulates GH release by activating the ghrelin/GH-secretagogue receptor (GHSR1a) on the pituitary and hypothalamus, an action that also requires intact endogenous GHRH signaling for a maximal GH response.

Separately, its binding to CD36 is linked to non-GH cytoprotective effects observed in animal tissue-injury models. [INFOGRAPHIC: Ghrelin-receptor GH secretagogue signalling]

What does the research say about GHRP-6?

  • Intravenous GHRP-6 stimulates GH release in humans, but a GHRH antagonist eliminated most of that response, showing endogenous hypothalamic GHRH is needed for the maximal effect. [1]
  • During a 34-hour infusion in normal men the pituitary did not desensitize; GHRP-6 augmented pulsatile GH secretion, behaving in part like a functional somatostatin antagonist. [2]
  • In a rat permanent-coronary-ligation model, GHRP-6 reduced post-infarct ventricular remodeling and fibrosis and improved left-ventricular systolic function (preclinical only). [6]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation — Pandya N et al., J Clin Endocrinol Metab 1998. (human controlled trial (9 healthy men))
  • [2] Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men — Jaffe CA et al., J Clin Endocrinol Metab 1993. (human study (9 normal men, 34-h infusion))
  • [3] Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature — Bellone J et al., Eur J Endocrinol 1995. (human clinical (children with short stature))
  • [4] Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure — Cibrian D et al., Clin Sci (Lond) 2006. (animal (rat ischemia/reperfusion))
  • [5] Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms — Berlanga-Acosta J et al., Front Pharmacol 2024. (animal (rats))
  • [6] Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation — Wang L et al., Pharmaceuticals (Basel) 2026. (animal (rat permanent coronary ligation))

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Human studies typically used small intravenous amounts (for example around 1 microgram/kg as a GH-stimulation bolus, with higher weight-based doses in pharmacokinetic work), and pediatric work explored oral administration.

These reflect experimental study conditions rather than any recommended regimen; GHRP-6 is presented strictly as a research compound.

Side effects & safety profile

Human exposure in the literature is largely limited to short GH-stimulation and pharmacokinetic studies, so long-term safety in humans is not established.

As a ghrelin-receptor agonist it can stimulate appetite, and GH secretagogues of this class may transiently affect cortisol and prolactin, especially at higher doses.

GHRP-6 is not approved for any indication; the promising cardioprotective and cytoprotective findings are almost entirely from animal and in-vitro models and have not been confirmed in controlled human trials.

Stacking & combinations

In research contexts GHRP-6 is frequently paired with a GHRH analog (such as sermorelin or CJC-1295) to combine the ghrelin and GHRH pathways for greater GH release, but such combinations are experimental with no validated human safety data.

Finding GHRP-6 vendors

Finding GHRP-6 vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

GHRP-6 acts on the ghrelin/GH-secretagogue receptor, whereas sermorelin acts on the GHRH receptor; the two pathways can act together to release GH.

References

  1. [1] Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation — Pandya N et al., J Clin Endocrinol Metab 1998. PMID: 9543138. View sourceStudy: human controlled trial (9 healthy men)Blocking GHRH with an antagonist eliminated most of the GH response to GHRP-6, indicating GHRH-dependence.
  2. [2] Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men — Jaffe CA et al., J Clin Endocrinol Metab 1993. PMID: 7903313. View sourceStudy: human study (9 normal men, 34-h infusion)The pituitary stayed responsive without desensitization; GHRP augmented pulsatile GH amplitude.
  3. [3] Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature — Bellone J et al., Eur J Endocrinol 1995. PMID: 7581965. View sourceStudy: human clinical (children with short stature)Oral GHRP-6 elicited a GH response comparable to that of GHRH.
  4. [4] Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure — Cibrian D et al., Clin Sci (Lond) 2006. PMID: 16417467. View sourceStudy: animal (rat ischemia/reperfusion)GHRP-6 markedly reduced hepatic and intestinal ischemia/reperfusion injury, supporting cytoprotection.
  5. [5] Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms — Berlanga-Acosta J et al., Front Pharmacol 2024. PMID: 38873418. View sourceStudy: animal (rats)GHRP-6 prevented doxorubicin-induced cardiac and organ damage via antioxidant and pro-survival pathways.
  6. [6] Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation — Wang L et al., Pharmaceuticals (Basel) 2026. PMID: 41901314. View sourceStudy: animal (rat permanent coronary ligation)GHRP-6 attenuated post-infarct remodeling and fibrosis and improved left-ventricular systolic function.

Related peptides

GHRP-2Growth HormoneHexarelinGrowth HormoneIpamorelinGrowth Hormone
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.